查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
抗病毒联合疗法市场，按药物组合、副产品、分销管道、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测
市场调查报告书
商品编码
1351389

抗病毒联合疗法市场，按药物组合、副产品、分销管道、国家和地区 - 2023-2030 年行业分析、市场规模、市场份额和预测

Antiviral Combination Therapies Market, By Drug Combination, By Product, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 246 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2022 年抗病毒联合疗法市场规模为 468.06 亿美元，2023 年至 2030 年复合年增长率为 4.8%。

抗病毒联合疗法市场 - 市场动态：

  • 病毒感染的日益普及推动了市场的成长
  • 病毒感染的日益流行预计将在预测期内推动市场成长。每年，世界上相当一部分人口受到病毒性疾病的影响，包括 HIV/AIDS、肝炎、COVID-19、流感和疱疹。与单一药物治疗相比，抗病毒联合药物具有多种优势，包括更能延迟或抑制抗药性的发展。此外，抗病毒联合疗法已成为治疗丙型肝炎和爱滋病毒等慢性病毒性疾病的黄金标准。抗病毒联合药物透过利用高效抗逆转录病毒疗法来降低抗药性和限制病毒传播，在爱滋病毒治疗中发挥重要作用。 NCBI称，这些组合药物除了有效治疗流感等急性病毒感染外，还可降低抗药性、抑制病毒繁殖、提高疗效、降低死亡率。因此，预计这将推动市场成长。

抗病毒联合疗法市场 - 主要见解：

  • 根据我们的研究分析师分享的分析，全球抗病毒联合疗法市场预计在预测期内（2023-2030 年）每年将以 4.8% 左右的复合年增长率成长
  • 由于病毒感染流行率不断上升，抗病毒联合疗法产业预计将以显着的速度成长。
  • 根据药物组合，RTI/NNRTI 细分市场预计将在预测期内主导市场。
  • 从地区来看，预计北美将在预测期内主导市场。

抗病毒联合疗法市场細項分析：

  • 全球抗病毒联合疗法市场根据药物组合、产品、分销管道和地区进行细分。
  • 根据药物组合，全球抗病毒联合疗法市场分为 RTI/NNRTI、整合酶抑制剂/NRTI、NRTI、NRTI/蛋白酶抑制剂等。预计 RTI/NNRTI 领域将在预测期内主导市场。 RTI/NNRTI 综合药物在抗病毒联合治疗领域，特别是在爱滋病毒/爱滋病的治疗领域具有重要意义，可以归功于这种扩张。它有助于阻止病毒扩散。此外，NRTI 是 RTI 的一个亚类，是模仿病毒 DNA 链中天然核苷酸的核苷类似物，其主要目标是阻止病毒 DNA 的产生。

抗病毒联合疗法市场 - 地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太、中东和非洲等地区。这些区域根据开展业务的国家进一步划分。由于爱滋病毒、肝炎、流感等疾病的盛行率不断上升，预计北美将在预测期内主导市场。此外，重要製药企业的存在以及持续的研发项目也将大大促进北美市场的扩张。另一方面，预计亚太地区在预测期内将以最高的复合年增长率成长。该地区的市场成长归功于製药业的发展和政府措施的增加。

抗病毒联合疗法市场-竞争格局：

市场的主要参与者包括：默克公司、ViiV Healthcare、吉利德科学公司、艾伯维公司、杨森製药、百时美施贵宝、勃林格殷格翰製药公司、罗氏控股公司、Mylan NV 和 Cipla Ltd 。

最近的发展：

2023 年 2 月，Atea Pharmaceuticals 公布了 AT-527（一种 COVID-19 容量治疗药物）的 2 期临床研究的令人印象深刻的结果。一种名为 AT-527 的小化学物质会干扰 SARS-CoV-2 病毒的进入机制。这项突破可能会改善抗病毒组合治疗的商业环境。

研究的主要特点：

  • 这项关于抗病毒联合疗法市场的建议研究提供了市场规模（百万美元）、年复合成长率（CAGR%）和预测估计（2023-2030），以 2022 年为基准年
  • 该报告为客户提供有关抗病毒联合疗法市场的最新趋势见解。
  • 该研究报告阐明了不同细分市场/国家的潜在成长机会，并解释了抗病毒联合疗法市场有吸引力的投资主张矩阵
  • 总体报告确定了新的投资机会、老牌参与者面临的挑战以及抗病毒联合疗法市场维持的成长因素
  • COVID-19 对抗病毒联合疗法市场规模、预测、复合年增长率和市场动态的影响将在研究范围下详细讨论。也将详细介绍新冠疫情后抗病毒联合疗法市场的情况。
  • 为了让本报告的使用者全面了解抗病毒联合疗法市场，我们还包括了抗病毒联合疗法市场的竞争格局和关键创新者分析。
  • 该研究包括成长前景映射分析，其中所有行业细分都根据其市场规模、成长率和吸引力进行基准测试。
  • 该报告提供了主要市场参与者的详细公司概况，这将帮助用户了解抗病毒联合疗法市场参与者的财务资讯和策略倡议。
  • 此外，报告还公布了全球和区域市场主要参与者的重要收购和合併、合作和合资、新产品推出、研发、区域扩张。
  • 全球抗病毒联合疗法市场报告主要针对该行业的各个利益相关者，包括供应商、投资者、新进业者、经销商和财务分析师

目录

第 1 章：抗病毒联合疗法市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 抗病毒联合疗法市场片段（按药物组合）
    • 抗病毒联合疗法市场片段（按产品）
    • 按分销管道分類的抗病毒联合疗法市场片段
    • 按国家/地区分類的抗病毒联合疗法市场片段
    • 按地区分類的抗病毒联合疗法市场片段
  • 竞争洞察

第 3 章：抗病毒联合疗法主要市场趋势

  • 抗病毒联合疗法市场驱动因素
    • 市场驱动因素的影响分析
  • 抗病毒联合疗法市场限制
    • 市场限制影响分析
  • 抗病毒联合疗法的市场机会
  • 抗病毒联合疗法市场未来趋势

第 4 章：抗病毒联合疗法产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：抗病毒联合疗法市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：抗病毒联合疗法市场格局

  • 2022 年抗病毒联合疗法市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：抗病毒联合疗法市场 - 按药物组合

  • 概述
    • 按药物组合分類的细分市场份额分析
    • 逆转录酶抑制剂/非逆转录酶抑制剂
    • 整合酶抑制剂/NRTI
    • 核苷类逆转录酶抑制剂
    • NRTI/蛋白酶抑制剂
    • 其他的

第 8 章：抗病毒联合疗法市场 - 副产品

  • 概述
    • 按产品分類的细分市场占有率分析
    • 品牌化
    • 通用的

第 9 章：抗病毒联合疗法市场 - 按分销管道

  • 概述
    • 按分销管道分類的细分市场份额分析
    • 医院药房
    • 零售药局
    • 其他的

第 10 章：抗病毒联合疗法市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美抗病毒联合疗法主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物组合）
    • 北美市场规模和预测（按产品）
    • 北美市场规模和预测（按分销管道）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲抗病毒联合疗法主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物组合）
    • 欧洲市场规模与预测（按产品）
    • 欧洲市场规模和预测（按分销管道）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区抗病毒联合疗法主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 按药物组合分類的亚太市场规模和预测
    • 亚太地区市场规模与预测（按产品）
    • 亚太地区市场规模和预测（按分销管道）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗病毒联合疗法主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物组合）
    • 拉丁美洲市场规模与预测（按产品）
    • 拉丁美洲市场规模和预测（按分销管道）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲抗病毒联合疗法主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物组合）
    • 中东和非洲市场规模及预测（按产品）
    • 中东和非洲市场规模及预测（按分销管道）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 抗病毒联合疗法产业

  • 竞争仪表板
  • 公司简介
    • Merck & Co. Inc.
    • ViiV Healthcare
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Janssen Pharmaceuticals
    • Bristol Myers Squibb
    • Boehringer Ingelheim Pharmaceuticals Inc.
    • Roche Holding AG
    • Mylan NV
    • Cipla Ltd.

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: ANV1684

REPORT HIGHLIGHT

Antiviral Combination Therapies Market size was valued at USD 46,806 Million in 2022, expanding at a CAGR of 4.8% from 2023 to 2030.

Antiviral combination treatments, sometimes referred to as aggregate antiviral therapy (CART), include using several antiviral medications together to treat viral infections. This method includes combining various antiviral drugs that target various viral replication cycle components or individual viral traces to increase treatment efficacy and lower the risk of drug resistance. Antiviral aggregate treatment is necessary because viruses frequently have rapid mutation rates, which enable them to quickly adapt and build up resistance to single capsules.

Antiviral Combination Therapies Market - Market Dynamics:

  • The growing prevalence of viral infection drives the market growth
  • The growing prevalence of viral infection is expected to drive market growth during the forecast period. Each year, a sizable fraction of the world's population is impacted by viral illnesses including HIV/AIDS, hepatitis, COVID-19, influenza, and herpes. Compared to single-drug therapy, antiviral combination medicines have several advantages, including a greater ability to postpone or inhibit the development of drug resistance. Additionally, antiviral combination therapy has established itself as the gold standard for the treatment of chronic viral diseases including HCV and HIV. Antiviral combination medicines have been essential in the treatment of HIV by utilizing highly active antiretroviral therapy for lowering drug resistance and limiting virus transmission. In addition to effectively treating acute viral infections like influenza, these combination medicines, according to NCBI, can also lower drug resistance, inhibit viral reproduction, improve efficiency, and lower the mortality rate. Thus, this is expected to drive the market growth.

Antiviral Combination Therapies Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Antiviral Combination Therapies market is estimated to grow annually at a CAGR of around 4.8% over the forecast period (2023-2030)
  • The antiviral Combination Therapies industry is projected to grow at a significant rate owing to the growing prevalence of viral infection.
  • Based on the drug combination, the RTI/NNRTI segment is expected to dominate the market during the forecast period.
  • Based on region, North America is expected to dominate the market over the forecast period.

Antiviral Combination Therapies Market- Segmentation Analysis:

  • The Global Antiviral Combination Therapies Market is segmented based on Drug Combination, Product, Distribution Channel and Region.
  • Based on the drug combination, the global Antiviral Combination Therapies market is segmented into RTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others. The RTI/NNRTI segment is expected to dominate the market during the forecast period. RTI/NNRTI aggregate medicines, which are significant in the field of antiviral combination treatments, notably in the treatment of HIV/AIDS, can be credited with the expansion. It aids in putting a stop to viral proliferation. Additionally, NRTIs, a subgroup of RTIs, are nucleoside analogs that imitate the natural nucleotides found in the viral DNA chain with the primary goal of stopping viral DNA production.

Antiviral Combination Therapies Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period due to the increasing prevalence of HIV, Hepatitis, Influenza and others. Moreover, the market's expansion in North America will also be significantly aided by the presence of important pharmaceutical businesses as well as continuing research and development projects. On the other hand, the Asia Pacific is expected to grow at the highest CAGR during the forecast period. The market growth in the region is attributed to the growing pharmaceutical industry and increasing government initiatives.

Antiviral Combination Therapies Market- Competitive Landscape:

The key players operating in the market are: Merck & Co. Inc., ViiV Healthcare, Gilead Sciences Inc., AbbVie Inc., Janssen Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals Inc., Roche Holding AG, Mylan N.V. and Cipla Ltd.

Recent Developments:

In February 2023, Atea Pharmaceuticals unveiled impressive findings from a Phase 2 clinical study of AT-527, a COVID-19 capacity treatment. A small chemical called AT-527 interferes with the SARS-CoV-2 virus's entrance mechanism. This breakthrough may improve the commercial environment for antiviral combo treatments.

Key features of the study:

  • This proposed research study on Antiviral Combination Therapies market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Antiviral Combination Therapies market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Antiviral Combination Therapies market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Antiviral Combination Therapies market
  • Impact of COVID-19 on Antiviral Combination Therapies market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Antiviral Combination Therapies market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Antiviral Combination Therapies market, we have also included competitive landscape and key innovator analysis for the Antiviral Combination Therapies market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Antiviral Combination Therapies market.
  • In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Antiviral Combination Therapies market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET KEY PLAYERS

  • Merck & Co. Inc.
  • ViiV Healthcare
  • Gilead Sciences Inc.
  • AbbVie Inc.
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Roche Holding AG
  • Mylan N.V.
  • Cipla Ltd.

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY DRUG COMBINATION

  • RTI/NNRTI
  • Integrase Inhibitor/NRTI
  • NRTI
  • NRTI/Protease Inhibitor
  • Others

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY PRODUCT

  • Branded
  • Generic

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Antiviral Combination Therapies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antiviral Combination Therapies Market Snippet by Drug Combination
    • 2.1.2. Antiviral Combination Therapies Market Snippet by Product
    • 2.1.3. Antiviral Combination Therapies Market Snippet by Distribution Channel
    • 2.1.4. Antiviral Combination Therapies Market Snippet by Country
    • 2.1.5. Antiviral Combination Therapies Market Snippet by Region
  • 2.2. Competitive Insights

3. Antiviral Combination Therapies Key Market Trends

  • 3.1. Antiviral Combination Therapies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antiviral Combination Therapies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antiviral Combination Therapies Market Opportunities
  • 3.4. Antiviral Combination Therapies Market Future Trends

4. Antiviral Combination Therapies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antiviral Combination Therapies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antiviral Combination Therapies Market Landscape

  • 6.1. Antiviral Combination Therapies Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antiviral Combination Therapies Market - By Drug Combination

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Combination, 2022 & 2030 (%)
    • 7.1.2. RTI/NNRTI
    • 7.1.3. Integrase Inhibitor/NRTI
    • 7.1.4. NRTI
    • 7.1.5. NRTI/Protease Inhibitor
    • 7.1.6. Others

8. Antiviral Combination Therapies Market - By Product

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Product, 2022 & 2030 (%)
    • 8.1.2. Branded
    • 8.1.3. Generic

9. Antiviral Combination Therapies Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Others

10. Antiviral Combination Therapies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Antiviral Combination Therapies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Antiviral Combination Therapies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Antiviral Combination Therapies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Antiviral Combination Therapies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Antiviral Combination Therapies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Antiviral Combination Therapies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co. Inc.
    • 11.2.2. ViiV Healthcare
    • 11.2.3. Gilead Sciences Inc.
    • 11.2.4. AbbVie Inc.
    • 11.2.5. Janssen Pharmaceuticals
    • 11.2.6. Bristol Myers Squibb
    • 11.2.7. Boehringer Ingelheim Pharmaceuticals Inc.
    • 11.2.8. Roche Holding AG
    • 11.2.9. Mylan N.V.
    • 11.2.10. Cipla Ltd.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Antiviral Combination Therapies Market: Drug Combination Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Combination
  • TABLE Global Antiviral Combination Therapies Market, by Drug Combination 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Product Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Product
  • TABLE Global Antiviral Combination Therapies Market, by Product 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Antiviral Combination Therapies Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Antiviral Combination Therapies Market, by Region 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)